RESUMEN
BACKGROUND: Critical illness myopathy and/or neuropathy (CRIMYNE) is a common alteration seen in the ICU. The currently available bedside methods of measuring respiratory and peripheral muscle function in critically ill patients are somewhat inadequate. The objective of this study was to evaluate the presence of diaphragmatic and peripheral CRIMYNE in septic patients with prolonged weaning from mechanical ventilation (MV). METHODS: Cohort prospective study with an entry period of 6 months. In 2 Brazilian medical-surgical ICUs, septic patients ≥ 18 years of age, dependent on MV ≥ 14 days, requiring prolonged weaning from MV, awake (Richmond Agitation Sedation Scale ≥ -2), and with no previous history of polyneuropathy or myopathy were included. Electrophysiological studies of the limbs and also of the respiratory system by phrenic nerve conduction and needle electromyography of the diaphragm were performed in all subjects. RESULTS: Twelve subjects were enrolled during 6 months of study. The electrophysiological signs of peripheral CRIMYNE occurred in 9 subjects, 7 of whom died in the ICU. Three subjects developed critical illness polyneuropathy, 4 critical illness myopathy, and 2 both. Only one subject who developed peripheral CRIMYNE did not present diaphragmatic involvement, whereas no subject developed diaphragm involvement alone. Thus, electrophysiological signs of diaphragmatic CRIMYNE occurred in 8 of the 9 subjects with peripheral CRIMYNE. Upon clinical examination, 8 subjects were not able to moves their limbs against gravity, and these findings were related to the presence of peripheral and diaphragmatic dysfunction. CONCLUSIONS: Our pilot findings suggested that CRIMYNE is common in septic patients with prolonged weaning from MV (MV ≥ 14 d). The inability to move limbs against gravity is frequently associated with peripheral and diaphragmatic CRIMYNE, and the findings of CRIMYNE in peripheral electrophysiological tests are associated with diaphragmatic involvement.
Asunto(s)
Diafragma/fisiopatología , Enfermedades Musculares/fisiopatología , Nervio Frénico/fisiopatología , Polineuropatías/fisiopatología , Respiración Artificial/efectos adversos , Desconexión del Ventilador/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Distribución de Chi-Cuadrado , Enfermedad Crítica , Electromiografía , Femenino , Humanos , Extremidad Inferior/fisiopatología , Masculino , Persona de Mediana Edad , Enfermedades Musculares/etiología , Conducción Nerviosa , Proyectos Piloto , Polineuropatías/etiología , Estudios Prospectivos , Sepsis/complicaciones , Estadísticas no Paramétricas , Factores de Tiempo , Extremidad Superior/fisiopatologíaRESUMEN
PURPOSE: To investigate the association between the clinical evaluation and self-perception of deglutition with the motor disability scale in patients with Multiple Sclerosis. METHODS: It is a cross-sectional, prospective study that was conducted with individuals with Multiple Sclerosis treated by the Neuroimmunology outpatient clinic of a hospital in southern Brazil. We reviewed the electronic medical records of patients to extract the score from the last Expanded Disability Status Scale. After the analysis of the inclusion criteria, and in clinical consultation, two protocols were applied: one of self-perception for the risk of dysphagia, through the Brazilian equivalence instrument of the Eating Assessment Tool; and the clinical evaluation of swallowing, with food, through the scale Gugging Swallowing Screen. The data were analyzed through tables, descriptive statistics and the tests: Fisher's Exact Association Test and Chi-square Test to assess the association between the results of the applied scales. We considered a maximum significance level of 5% (p <0.05). RESULTS: It was possible to observe that there was a significant association between the scores of the Gugging Swallowing Screen scales with the Expanded Disability Status Scale of the patients. In addition, there was also a relation between the results of both protocols with the Expanded Disability Status Scale. CONCLUSION: The patients with Multiple Sclerosis in this study presented oropharyngeal dysphagia, what was confirmed by the association between the clinical evaluation of swallowing and the results of the instrument of self-perception of swallowing and the motor disability scale.
OBJETIVO: Investigar a associação entre a avaliação clínica e autopercepção da deglutição com a escala de incapacidade motora em pacientes com Esclerose Múltipla. MÉTODO: Estudo transversal, prospectivo realizado com indivíduos com Esclerose Múltipla atendidos pelo ambulatório de Neuroimunologia de um hospital do sul do Brasil. Realizamos a revisão dos prontuários eletrônicos dos pacientes para extração do escore da última Expanded Disability Status Scale. Após a análise dos critérios de inclusão, e em consulta clínica, foram aplicados dois protocolos, o de autopercepção para o risco de disfagia, através do instrumento de equivalência brasileira do Eating Assessment Tool e a avaliação clínica da deglutição, com alimentos, através da escala Gugging Swallowing Screen. Os dados foram analisados através de tabelas, estatísticas descritivas e pelos testes: Teste de Associação Exato de Fisher e Teste Qui-quadrado para avaliar a associação entre os resultados das escalas aplicadas. Consideramos um nível de significância máximo de 5% (p<0,05). RESULTADOS: Foi possível observar que houve associação significativa entre os escores das escalas Gugging Swallowing Screen com a Expanded Disability Status Scale dos pacientes. Além disso, também se observou relação entre os resultados de ambos protocolos com a Expanded Disability Status Scale. CONCLUSÃO: Os pacientes com Esclerose Múltipla deste estudo apresentaram disfagia orofaríngea. Houve associação entre os achados da avaliação clínica, do instrumento de autopercepção da deglutição e da escala de incapacidade motora em pacientes com esclerose múltipla.
Asunto(s)
Trastornos de Deglución , Personas con Discapacidad , Trastornos Motores , Esclerosis Múltiple , Estudios Transversales , Deglución , Trastornos de Deglución/diagnóstico , Trastornos de Deglución/etiología , Evaluación de la Discapacidad , Humanos , Esclerosis Múltiple/complicaciones , Estudios Prospectivos , AutoimagenRESUMEN
The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.
Asunto(s)
COVID-19 , Esclerosis Múltiple , Neurología , Sistema Nervioso Central , Humanos , Esclerosis Múltiple/tratamiento farmacológico , SARS-CoV-2 , VacunaciónRESUMEN
BACKGROUND AND OBJECTIVES: To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD). METHODS: The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described. RESULTS: Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8-77), with disease onset at 31 years (range 4-69) and disease duration of 6 years (range 0.2-20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection. DISCUSSION: Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.
Asunto(s)
COVID-19/fisiopatología , Hospitalización/estadística & datos numéricos , Neuromielitis Óptica/fisiopatología , Adolescente , Adulto , Anciano , Brasil/epidemiología , COVID-19/epidemiología , COVID-19/terapia , Niño , Progresión de la Enfermedad , Femenino , Humanos , Inmunosupresores/uso terapéutico , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Neuromielitis Óptica/tratamiento farmacológico , Neuromielitis Óptica/epidemiología , Recurrencia , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Medulloblastoma (MB) is the most common malignant brain tumor in childhood. The alterations found include: presence of oncoproteins p53 and HER2, elevated mitotic index, and presence of neuronal differentiation. The aim of this study was to determine the immunohistochemical expression of markers Ki-67, NeuN, synaptophysin, HER2 and p53 in 40 MB samples and their correlation with clinicopathologic parameters and survival. In 29 patients (72.5%), >20% of cells were positive for Ki-67. Males showed greater ki-67 expression (p=0.02) and smaller survival rates (p=0.002). NeuN and synaptophysin were negative in 16 (40%) and 8 (20%) cases, respectively. P53 was positive in 18 (45%) cases, with 11 (61%) weakly positive and 7 (39%) strongly positive. HER2 was positive in 23 (57.5%) of the samples and did not show statistical association with survival (p=0.07).
Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias Cerebelosas/patología , Meduloblastoma/patología , Adolescente , Antígenos Nucleares/metabolismo , Brasil/epidemiología , Neoplasias Cerebelosas/metabolismo , Neoplasias Cerebelosas/mortalidad , Niño , Preescolar , Métodos Epidemiológicos , Femenino , Humanos , Lactante , Antígeno Ki-67/metabolismo , Masculino , Meduloblastoma/metabolismo , Meduloblastoma/mortalidad , Neoplasia Residual , Proteínas del Tejido Nervioso/metabolismo , Receptor ErbB-2/metabolismo , Sinaptofisina/metabolismo , Proteína p53 Supresora de Tumor/metabolismoRESUMEN
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). OBJECTIVE: To identify the serologic profile of JCV in patients with MS. METHODS: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. RESULTS: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. CONCLUSION: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
Asunto(s)
Anticuerpos Antivirales/sangre , Virus JC/inmunología , Leucoencefalopatía Multifocal Progresiva/inmunología , Esclerosis Múltiple/virología , Infecciones por Polyomavirus/inmunología , Adulto , Brasil/epidemiología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Leucoencefalopatía Multifocal Progresiva/sangre , Masculino , Esclerosis Múltiple/sangre , Esclerosis Múltiple/tratamiento farmacológico , Natalizumab/efectos adversos , Infecciones por Polyomavirus/epidemiología , Prevalencia , Seroconversión , Factores SexualesRESUMEN
RESUMO Objetivo Investigar a associação entre a avaliação clínica e autopercepção da deglutição com a escala de incapacidade motora em pacientes com Esclerose Múltipla. Método Estudo transversal, prospectivo realizado com indivíduos com Esclerose Múltipla atendidos pelo ambulatório de Neuroimunologia de um hospital do sul do Brasil. Realizamos a revisão dos prontuários eletrônicos dos pacientes para extração do escore da última Expanded Disability Status Scale. Após a análise dos critérios de inclusão, e em consulta clínica, foram aplicados dois protocolos, o de autopercepção para o risco de disfagia, através do instrumento de equivalência brasileira do Eating Assessment Tool e a avaliação clínica da deglutição, com alimentos, através da escala Gugging Swallowing Screen. Os dados foram analisados através de tabelas, estatísticas descritivas e pelos testes: Teste de Associação Exato de Fisher e Teste Qui-quadrado para avaliar a associação entre os resultados das escalas aplicadas. Consideramos um nível de significância máximo de 5% (p<0,05). Resultados Foi possível observar que houve associação significativa entre os escores das escalas Gugging Swallowing Screen com a Expanded Disability Status Scale dos pacientes. Além disso, também se observou relação entre os resultados de ambos protocolos com a Expanded Disability Status Scale. Conclusão Os pacientes com Esclerose Múltipla deste estudo apresentaram disfagia orofaríngea. Houve associação entre os achados da avaliação clínica, do instrumento de autopercepção da deglutição e da escala de incapacidade motora em pacientes com esclerose múltipla.
ABSTRACT Purpose To investigate the association between the clinical evaluation and self-perception of deglutition with the motor disability scale in patients with Multiple Sclerosis. Methods It is a cross-sectional, prospective study that was conducted with individuals with Multiple Sclerosis treated by the Neuroimmunology outpatient clinic of a hospital in southern Brazil. We reviewed the electronic medical records of patients to extract the score from the last Expanded Disability Status Scale. After the analysis of the inclusion criteria, and in clinical consultation, two protocols were applied: one of self-perception for the risk of dysphagia, through the Brazilian equivalence instrument of the Eating Assessment Tool; and the clinical evaluation of swallowing, with food, through the scale Gugging Swallowing Screen. The data were analyzed through tables, descriptive statistics and the tests: Fisher's Exact Association Test and Chi-square Test to assess the association between the results of the applied scales. We considered a maximum significance level of 5% (p <0.05). Results It was possible to observe that there was a significant association between the scores of the Gugging Swallowing Screen scales with the Expanded Disability Status Scale of the patients. In addition, there was also a relation between the results of both protocols with the Expanded Disability Status Scale. Conclusion The patients with Multiple Sclerosis in this study presented oropharyngeal dysphagia, what was confirmed by the association between the clinical evaluation of swallowing and the results of the instrument of self-perception of swallowing and the motor disability scale.
RESUMEN
Objective: Vitamin D has taken center stage in research and treatment of multiple sclerosis (MS). The objective of the present study was to assess the serum vitamin D levels of a large population of patients with MS and controls living in a restricted tropical area. Methods: Data from 535 patients with MS and 350 control subjects were obtained from 14 cities around the Tropic of Capricorn. Results: The mean serum 25-OH vitamin D level was 26.07 ± 10.27 ng/mL for the control subjects, and 28.03 ± 12.19 ng/mL for patients with MS. No correlation was observed between vitamin D levels and the disability of patients over the disease duration. Conclusion: At least for the region around the Tropic of Capricorn, serum levels of vitamin D typically are within the range of 20 to 30 ng/mL for controls and patients with MS.
Asunto(s)
Esclerosis Múltiple/sangre , Deficiencia de Vitamina D/sangre , Vitamina D/sangre , Adulto , Brasil , Estudios de Casos y Controles , Evaluación de la Discapacidad , Progresión de la Enfermedad , Femenino , Geografía Médica , Humanos , Masculino , Esclerosis Múltiple/complicaciones , Deficiencia de Vitamina D/complicacionesRESUMEN
Gliomatosis cerebri (GC) is a rare form of CNS neoplasia in which there is diffuse involvement of the nervous tissue with or without the presence of tumor mass. The origin of the tumor is unknown, nor whether it represents a disease with diffuse onset or infiltration from a neoplastic focus. Here we studied the histopathologic characteristics of 6 cases with a diagnosis of GC and performed an immunohistochemical analysis using glial fibrillary acidic protein (GFAP), synaptophysin, nestin and vimentin. Most tumor cells were negative for GFAP, even though there were foci of positivity for this marker in all cases. We detected the presence of many positive cells for nestin and vimentin in all studied samples. The presence of these cells may indicate origin of the tumor from undifferentiated cells with a high degree of mobility.
Asunto(s)
Astrocitoma/metabolismo , Biomarcadores de Tumor/análisis , Neoplasias Encefálicas/metabolismo , Proteínas de Filamentos Intermediarios/análisis , Proteínas del Tejido Nervioso/análisis , Vimentina/análisis , Adolescente , Adulto , Astrocitoma/patología , Neoplasias Encefálicas/patología , Niño , Femenino , Proteína Ácida Fibrilar de la Glía/análisis , Humanos , Inmunohistoquímica , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Nestina , Sinaptofisina/análisis , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: To associate the degree of biomechanical impairment in the swallowing process with the severity (National Institute of Health Stroke Scale - NIHSS) and type of neurological injury in patients post stroke. METHODS: A cross-sectional, descriptive study conducted with 42 patients (22 females), aged 65.7 years on average diagnosed with stroke. All patients underwent clinical neurological evaluation and application of the NIHSS in the first 48 hours after stroke. The swallowing function was evaluated using the Functional Oral Intake Scale (FOIS) and the Protocol for the Investigation of Oropharyngeal Dysphagia in Adults. The Fisher's Exact Probability Test was used to assess the correlation between the degree of swallowing impairment and the severity (NIHSS score) and type of stroke. The study results were statistically analyzed at 5% significance level (p≤0.05). RESULTS: 92.9% of the patients presented ischemic stroke; 59.5% presented impairment of the anterior cerebral circulation. Statistically significant correlation was found between the neurological scale (NIHSS) scores and the swallowing impairment scale (p=0.016). CONCLUSION: An association between stroke severity and oropharyngeal dysphagia severity was observed. A high proportion of patients with ischemic stroke with circulation affected in the anterior cerebral region presented severe oropharyngeal dysphagia. No statistically significant correlation was observed between the FOIS scale and stroke severity.
Asunto(s)
Trastornos de Deglución/etiología , Accidente Cerebrovascular/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Trastornos de Deglución/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Accidente Cerebrovascular/clasificación , Adulto JovenRESUMEN
BACKGROUND: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS). OBJECTIVE: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group. METHODS: Patients with MS and gait disorders were prescribed fampridine (10âmg twice a day), irrespectively of the degree of disability determined by MS. Neurological disability determined by MS was assessed with the expanded disability scale score (EDSS). Outcomes for efficacy and safety of the drug were evaluated by the 25 foot-walk test and by the adverse events of fampridine. RESULTS: The time taken to walk 25 feet decreased by 20% or more in 62 patients (70%). Twenty-five patients were considered to be non-responders to this treatment. Improvement in walking speed was independent of improvement of disability. Mild or moderate adverse events were reported in 8% of patients. CONCLUSION: Fampridine is an efficient and safe therapeutic option for patients with MS and gait disorders.
Asunto(s)
4-Aminopiridina/uso terapéutico , Trastornos Neurológicos de la Marcha/diagnóstico , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Esclerosis Múltiple/diagnóstico , Esclerosis Múltiple/tratamiento farmacológico , Bloqueadores de los Canales de Potasio/uso terapéutico , 4-Aminopiridina/farmacología , Adulto , Anciano , Femenino , Trastornos Neurológicos de la Marcha/epidemiología , Humanos , Acontecimientos que Cambian la Vida , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/epidemiología , Bloqueadores de los Canales de Potasio/farmacología , Estudios ProspectivosRESUMEN
ABSTRACT The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.
RESUMO O DC de Neuroimunologia da ABN e o BCTRIMS trazem, nesse documento, as recomendações sobre vacinação da população com doenças desmielinizantes do sistema nervoso central (SNC) contra infecções em geral e contra o coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2), causador da COVID-19. Destaca-se a gravidade do atual momento frente ao avanço da COVID-19 em nosso País, o que torna mais evidente e importante a criação de guia de referência para orientação aos médicos, pacientes e autoridades de saúde pública quanto à vacinação, meio efetivo e seguro no controle de determinadas doenças infecciosa. O DCNI/ABN e o BCTRIMS recomendam que os pacientes com doenças desmielinizantes do SNC (ex., EM e NMOSD) sejam constantemente monitorados, quanto a atualização do seu calendário vacinal, especialmente, no início ou antes da mudança do tratamento com uma droga modificadora de doença (DMD). É importante também salientar que as vacinas são seguras e os médicos devem estimular o seu uso em todos os pacientes. Evidentemente, deve ser dada especial atenção às vacinas com vírus vivos atenuados. Por fim, é importante que os médicos verifiquem qual DMD o paciente está em uso e quando foi feita a sua última dose, pois cada fármaco pode interagir de forma diferente com a indução da resposta imune.
Asunto(s)
Humanos , COVID-19 , Esclerosis Múltiple/tratamiento farmacológico , Neurología , Sistema Nervioso Central , Vacunación , SARS-CoV-2RESUMEN
In cerebral ischemic preconditioning (IPC), a first sublethal ischemia increases the resistance of neurons to a subsequent severe ischemia. Despite numerous studies, the mechanisms are not yet fully understood. Our goal is to develop an in vitro model of IPC on hippocampal organotypic slice cultures. Instead of anoxia, we chose to apply varying degrees of hypoxia that allows us various levels of insult graded from mild to severe. Cultures are exposed to combined oxygen and glucose deprivation (OGD) of varying intensities, ranging from mild to severe, assessing both the electrical activity and cell death. IPC was accomplished by exposure to the mildest ischemia condition (10% of O2 for 15 min) 24 h before the severe deprivation (5% of O2 for 30 min). Interestingly, IPC not only prevented delayed ischemic cell death 6 days after insult but also the transient loss of evoked potential response. The major interest and advantage of this system over both the acute slice preparation and primary cell cultures is the ability to simultaneously measure the delayed neuronal damage and neuronal function.
Asunto(s)
Potenciales Evocados/fisiología , Hipocampo/metabolismo , Hipoglucemia/metabolismo , Hipoxia/metabolismo , Precondicionamiento Isquémico/métodos , Animales , Muerte Celular/fisiología , Modelos Animales de Enfermedad , Glucosa/metabolismo , Hipocampo/citología , Neuronas/citología , Técnicas de Cultivo de Órganos , Oxígeno/metabolismo , Ratas , Índice de Severidad de la EnfermedadAsunto(s)
Selección de Paciente , Accidente Cerebrovascular/tratamiento farmacológico , Terapia Trombolítica , Isquemia Encefálica/tratamiento farmacológico , Hemorragia Cerebral/inducido químicamente , Hemorragia Cerebral/patología , Ensayos Clínicos como Asunto , Diagnóstico por Imagen , Humanos , Terapia Trombolítica/efectos adversosRESUMEN
UNLABELLED: Glioblastoma is the most common neuroectodermic tumor. It is also the most malignant one. Many genetic changes are found in glioblastomas, among them, the presence of oncoproteins p53 and blc-2, as well as a high mitotic level and the presence of apoptosis. The utility of such findings through immunohistochemistry for the prognosis of patients remains uncertain. Our objectives in this study were to verify the presence of apoptosis, blc-2, p53, and the proliferative index (MIB-1), through immunohistochemistry, in 30 glioblastomas obtained by surgical resection between August 2000 and August 2001, as well as correlations between those immunohistochemical variables and the patient's age and survival time. Correlations between immunohistochemical variables themselves were also examined. For correlation calculations, Pearson's and Spermann's correlations were used and the time of survival was calculated with the Kaplan-Meier method. RESULTS: No correlation was found between immunohistochemical variables and survival time. There was also no correlation between those variables and the patients' age. A moderate inverse correlation was found between the apoptotic index (AI) and the mitotic index (MI) (p = 0.058), besides an inverse correlation between blc-2 and MI. CONCLUSION: Our study has not demonstrated any of the examined immunohistochemical findings as having a predictive value in the prognosis of glioblastomas. A reverse correlation was found between AI and MI, which has already been demonstrated by a few studies, as well as an inverse correlation between blc-2 and MI. This finding can demonstrate blc-2 as having a pro-apoptotic role in this group of tumors.
Asunto(s)
Apoptosis , Neoplasias Encefálicas , Proliferación Celular , Glioblastoma , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteína p53 Supresora de Tumor/genética , Adolescente , Animales , Anticuerpos Monoclonales , Biomarcadores de Tumor , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Femenino , Glioblastoma/genética , Glioblastoma/mortalidad , Glioblastoma/patología , Humanos , Inmunohistoquímica/métodos , Etiquetado Corte-Fin in Situ/métodos , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Masculino , Ratones , Índice Mitótico , Mutación , Pronóstico , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Factores Sexuales , Estadísticas no Paramétricas , Tasa de Supervivencia , Proteína p53 Supresora de Tumor/metabolismoRESUMEN
UNLABELLED: Hippocampal sclerosis (HS) is the commonest pathology in epileptic patients undergoing temporal lobe epilepsy surgery. Beside, there are an increased density of corpora amylacea (CA) founded in 6 to 63% of those cases. OBJECTIVE: verify the presence of CA and the clinical correlates of their occurrence in a consecutive series of patients undergoing temporal surgery with diagnosis of HS. METHOD: We reviewed 72 hippocampus specimens from January 1997 to July 2000. Student's t test for independent, samples, ANOVA and Tukey test were performed for statistical analysis. RESULTS: CA were found in 35 patients (49%), whose mean epilepsy duration (28.7 years) was significantly longer than that group of patients without CA (19.5 years, p=0.001). Besides, when CA were found, duration was also significantly correlated with distribution within hippocampus: 28.7 years with diffuse distribution of CA, 15.4 with exclusively subpial and 17.4 years with distribution subpial plus perivascular (p=0.001). CONCLUSION: Our findings corroborate the presence of CA in patients with HS and suggest that a longer duration of epilepsy correlate with a more distribution of CA in hippocampus.
Asunto(s)
Epilepsia del Lóbulo Temporal/patología , Hipocampo/patología , Cuerpos de Inclusión/patología , Adolescente , Adulto , Edad de Inicio , Amilasas/análisis , Análisis de Varianza , Niño , Preescolar , Epilepsia del Lóbulo Temporal/cirugía , Femenino , Hipocampo/química , Humanos , Cuerpos de Inclusión/química , Lactante , Masculino , EsclerosisAsunto(s)
Encefalopatías/diagnóstico , Infecciones Fúngicas del Sistema Nervioso Central/diagnóstico , Paracoccidioidomicosis/diagnóstico , Antifúngicos/uso terapéutico , Encefalopatías/microbiología , Infecciones Fúngicas del Sistema Nervioso Central/terapia , Femenino , Humanos , Persona de Mediana Edad , Paracoccidioidomicosis/terapiaRESUMEN
OBJECTIVE: To assess the functional and psychological features of patients immediately after discharge from the intensive care unit. METHODS: Prospective cohort study. Questionnaires and scales assessing the degree of dependence and functional capacity (modified Barthel and Karnofsky scales) and psychological problems (Hospital Anxiety and Depression Scale), in addition to the Epworth Sleepiness Scale, were administered during interviews conducted over the first week after intensive care unit discharge, to all survivors who had been admitted to this service from August to November 2012 and had remained longer than 72 hours. RESULTS: The degree of dependence as measured by the modified Barthel scale increased after intensive care unit discharge compared with the data before admission (57 ± 30 versus 47 ± 36; p < 0.001) in all 79 participants. This impairment was homogeneous among all the categories in the modified Barthel scale (p < 0.001) in the 64 participants who were independent or partially dependent (Karnofsky score ≥ 40) before admission. The impairment affected the categories of personal hygiene (p = 0.01) and stair climbing (p = 0.04) only in the 15 participants who were highly dependent (Karnofsky score < 40) before admission. Assessment of the psychological changes identified mood disorders (anxiety and/or depression) in 31% of the sample, whereas sleep disorders occurred in 43.3%. CONCLUSIONS: Patients who remained in an intensive care unit for 72 hours or longer exhibited a reduced functional capacity and an increased degree of dependence during the first week after intensive care unit discharge. In addition, the incidence of depressive symptoms, anxiety, and sleep disorders was high among that population.
Asunto(s)
Ansiedad/epidemiología , Depresión/epidemiología , Unidades de Cuidados Intensivos , Alta del Paciente , Trastornos del Sueño-Vigilia/epidemiología , Actividades Cotidianas , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Recuperación de la Función , Factores de TiempoRESUMEN
ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
RESUMO As opções terapêuticas para esclerose múltipla (EM) modificaram-se ao longo dos últimos anos, trazendo uma nova categoria de drogas com melhor perfil de eficácia. No entanto, estas drogas vieram com um novo perfil de potenciais eventos adversos que exigem que o neurologista os reconheça bem e rapidamente. Uma das complicações mais temidas destes tratamentos para a EM é a leucoencefalopatia multifocal progressiva (LEMP), causada pela reativação do vírus John Cunningham (JCV). Objetivo: Identificar o perfil sorológico de JCV em pacientes com EM. Métodos: Dados sorológicos de JCV foram obtidos através do ensaio por enzimas imuno-adsorvidas (ELISA) fornecido pelo programa STRATIFY-JCV. Resultados: Um total de 1.501 testes sanguíneos foram obtidos de 1.102 pacientes com EM. O grupo teve 633 pacientes (57,1%) soropositivos para anticorpos anti-JCV e 469 pacientes negativos (42,9%). Vinte e três pacientes se tornaram posivitos após resultados iniciais negativos para anticorpos anti-JCV. A taxa de soroconversão foi 18,5% em 22 meses. Conclusão: O perfil sorológico do JCV e a soroconversão nos pacientes brasileiros foi semelhante àquela descrita em outros países.